CREATE TABLE table_main (
  id VARCHAR(255),
  name VARCHAR(255),
  strain VARCHAR(255),
  type VARCHAR(255),
  family VARCHAR(255),
  modification VARCHAR(255),
  alone VARCHAR(255),
  combination VARCHAR(255),
  immune_gene VARCHAR(255),
  source VARCHAR(255),
  origin VARCHAR(255),
  cell_line VARCHAR(255),
  concentration VARCHAR(255),
  vitro_toxicity VARCHAR(255),
  assay VARCHAR(255),
  vitro_virus_conc VARCHAR(255),
  vitro_result VARCHAR(255),
  organism VARCHAR(255),
  vvo_virus_conc VARCHAR(255),
  vivo_toxicity VARCHAR(255),
  vivo_result VARCHAR(255),
  delivery VARCHAR(255),
  pathway VARCHAR(255),
  immune_ally VARCHAR(255),
  clinical_trial VARCHAR(255),
  pmid VARCHAR(255)
);
INSERT INTO table_main
  (id,name,strain,type,family,modification,alone,combination,immune_gene,source,origin,cell_line,concentration,vitro_toxicity,assay,vitro_virus_conc,vitro_result,organism,vvo_virus_conc,vivo_toxicity,vivo_result,delivery,pathway,immune_ally,clinical_trial,pmid)
VALUES
  ('OV_1','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','50 MOI','59% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_2','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','100 MOI','56% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_3','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','200 MOI','49% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_4','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','50 MOI','90% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_5','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','100 MOI','78% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_6','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','200 MOI','78% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_7','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','50 MOI','70% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_8','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','100 MOI','60% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_9','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','PANC-1','Grown to 70% confluence','NA','MTT assay','200 MOI','38% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_10','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','10 MOI','70% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_11','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','50 MOI','58% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_12','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','100 MOI','38% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_13','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','10 MOI','100% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_14','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','50 MOI','95% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_15','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','100 MOI','94% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_16','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','10 MOI','77% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_17','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','50 MOI','72% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_18','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','MIAPaCa-2','Grown to 70% confluence','NA','MTT assay','100 MOI','58% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_19','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','1 MOI','70% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_20','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','5 MOI','58% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_21','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','10 MOI','38% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_22','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','1 MOI','100% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_23','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','5 MOI','95% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_24','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','10 MOI','94% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_25','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','1 MOI','77% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_26','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','5 MOI','72% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_27','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human lung cancer cell line','A549','Grown to 70% confluence','NA','MTT assay','10 MOI','58% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_28','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','5 MOI','80% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_29','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','10 MOI','78% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_30','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','20 MOI','40% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_31','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','5 MOI','90% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_32','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','10 MOI','82% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_33','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','20 MOI','84% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_34','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','5 MOI','89% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_35','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','10 MOI','94% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_36','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','ATCC','Human pancreatic cancer cell line','AsPC-1','Grown to 70% confluence','NA','MTT assay','20 MOI','94% cancer cell viability','No','No','NA','No response','NA','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_37','Adenovirus','oAd/DCN/LRP','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+6 cells','2.0E+10 VP (on 0, 2, and 4 days)','Slight hepatotoxicity','Reduction in tumor volume to 230 cubic millimeter compared to control 300 cubic millimeter after 46 days','Intravenously','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','IL-6 production increased by 3 folds as compared to normal','NA','26471393'),
  ('OV_38','Adenovirus','oAd/DCN/LRP-PEG','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with polyethylene glycol','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+4 cells','2.0E+10 VP (on 0, 2, and 4 days)','NA','Reduction in tumor volume to 198 cubic millimeter compared to control 300 cubic millimeter after 46 days','Intravenously','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_39','Adenovirus','oAd/DCN/LRP-PEG-NT','DNA','Adenoviridae','Insertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+4 cells','2.0E+10 VP (on 0, 2, and 4 days)','NA','Reduction in tumor volume to 100 cubic millimeter compared to control 300 cubic millimeter after 46 days','Intravenously','Inhibits Wnt/β-catenin and TGF-β1 signaling pathways','NA','NA','26471393'),
  ('OV_40','Adenovirus','AdCMV/GFP','DNA','Adenoviridae','Mutant with E1 deletion carrying a green fluorescent protein (GFP)','Yes','No','No','ATCC','Human lung cancer cell line','A549','Desnity of 1000000 in 60mm dish','Highly toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI','MTT assay','3.5 MOI','13% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26475304'),
  ('OV_41','Adenovirus','Ad dl1520','DNA','Adenoviridae','E1b mutant with 827-bp deletion and a point mutation with premature stop codon in the E1B55K coding region','Yes','No','No','ATCC','Human lung cancer cell line','A549','Desnity of 1000000 in 60mm dish','Minimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI','MTT assay','3.5 MOI','54% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26475304'),
  ('OV_42','Adenovirus','Ad-cycE','DNA','Adenoviridae','E1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette','Yes','No','No','ATCC','Human lung cancer cell line','A549','Desnity of 1000000 in 60mm dish','Minimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI','MTT assay','3.5 MOI','18% cancer cell viability','No','No','NA','No response','NA','NA','Activates CDK2 and targets the transcriptional repressor pRb','NA','26475304'),
  ('OV_43','Adenovirus','AdCMV/GFP','DNA','Adenoviridae','Mutant with E1 deletion carrying a green fluorescent protein (GFP)','Yes','No','No','ATCC','Murine lung cancer cell line','ED-1','Desnity of 1000000 in 60mm dish','Highly toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI','MTT assay','10 MOI','22% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26475304'),
  ('OV_44','Adenovirus','Ad dl1520','DNA','Adenoviridae','E1b mutant with 827-bp deletion and a point mutation with premature stop codon in the E1B55K coding region','Yes','No','No','ATCC','Murine lung cancer cell line','ED-1','Desnity of 1000000 in 60mm dish','Minimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI','MTT assay','10 MOI','55% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26475304'),
  ('OV_45','Adenovirus','Ad-cycE','DNA','Adenoviridae','E1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette','Yes','No','No','ATCC','Murine lung cancer cell line','ED-1','Desnity of 1000000 in 60mm dish','Minimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI','MTT assay','10 MOI','55% cancer cell viability','No','No','NA','No response','NA','NA','Activates CDK2 and targets the transcriptional repressor pRb','NA','26475304'),
  ('OV_46','Adenovirus','Ad-cycE','DNA','Adenoviridae','E1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Female FVB/NCr mice isograft for 5.0E+6 cells ED-1 murine lung cancer cell lines','1.5E+9  IFU (on 0, 2, 4 and 6 days)','NA','Reduction in tumor volume to 52 cubic millimeter compared to control 150 cubic millimeter after 36 days','Intratumorally','NA','Activates CDK2 and targets the transcriptional repressor pRb','NA','26475304'),
  ('OV_47','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','NA','MTT assay','0.1 MOI','57% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_48','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','No','Viral strain in combination with etoposide (0.5 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.67 CDI','MTT assay','0.1 MOI','24% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_49','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','No','Viral strain in combination with epirubicin (0.5 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.46 CDI','MTT assay','0.1 MOI','16% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_50','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','No','Viral strain in combination with doxorubicin (0.1 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.88 CDI','MTT assay','0.1 MOI','26% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_51','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','No','Viral strain in combination with vincristine (0.1 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.79 CDI','MTT assay','0.1 MOI','25% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_52','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','No','Viral strain in combination with colchcine (0.02 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.81 CDI','MTT assay','0.1 MOI','28% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_53','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','NA','MTT assay','0.1 MOI','18% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_54','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','No','Viral strain in combination with etoposide (0.5 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.27 CDI','MTT assay','0.1 MOI','4% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_55','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','No','Viral strain in combination with epirubicin (0.5 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.31 CDI','MTT assay','0.1 MOI','4% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_56','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','No','Viral strain in combination with doxorubicin (0.1 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.33 CDI','MTT assay','0.1 MOI','6% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_57','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','No','Viral strain in combination with vincristine (0.1 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.89 CDI','MTT assay','0.1 MOI','12% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_58','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','No','Viral strain in combination with colchcine (0.02 μg/ml)','No','NA','Human lung cancer cell line','A549','1.0E+6 cells per well','0.78 CDI','MTT assay','0.1 MOI','10% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_59','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_60','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','0.1 MOI','90% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_61','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','1 MOI','40% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_62','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','10 MOI','2% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_63','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_64','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.01 MOI','90% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_65','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.1 MOI','60% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_66','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','1 MOI','4% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_67','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','10 MOI','1% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_68','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_69','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_70','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.1 MOI','96% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_71','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','1 MOI','80% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_72','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','10 MOI','20% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_73','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_74','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.1 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_75','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','1 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_76','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','10 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_77','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_78','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.1 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_79','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','1 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_80','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','10 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_81','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_82','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','0.1 MOI','85% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_83','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','1 MOI','35% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_84','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (YB-1 gene knockdown)','NA','NA','Crystal violet staining','10 MOI','1% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_85','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_86','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.01 MOI','90% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_87','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','0.1 MOI','20% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_88','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','1 MOI','2% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_89','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged YB-1 gene overexpressed)','NA','NA','Crystal violet staining','10 MOI','1% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_90','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_91','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_92','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','0.1 MOI','94% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_93','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','1 MOI','75% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_94','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','Human breast cancer line','MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)','NA','NA','Crystal violet staining','10 MOI','16% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26515462'),
  ('OV_95','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_96','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_97','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_98','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','10 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_99','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_100','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_101','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_102','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','10 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_103','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_104','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_105','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','1 MOI','NA','96% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_106','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)','10 MOI','NA','20% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_107','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_108','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_109','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_110','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','10 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_111','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_112','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_113','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_114','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','10 MOI','NA','40% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_115','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_116','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_117','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','1 MOI','NA','25% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_118','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IB)','10 MOI','NA','5% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_119','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_120','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_121','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_122','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','10 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_123','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_124','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','0.1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_125','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','1 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_126','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','10 MOI','NA','5% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_127','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','0.01 MOI','NA','100% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_128','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','0.1 MOI','NA','40% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_129','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','1 MOI','NA','10% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_130','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Clinical lung adenocarcinoma tissue (Primary cancer cells, Stage IV)','10 MOI','NA','5% cancer cell viability','NA','NA','NA','NA','26515462'),
  ('OV_131','Adenovirus','Ad5WS1','DNA','Adenoviridae','E1B55K-deleted mutant driven by the E1 promoter','No','Virus in combination with etoposide - 2mg/kg daily from day 5 to day 8','No','NA','NA','NA','NA','NA','NA','NA','NA','Male NOD/SCID mice (subcutaneously injected A549 lung cancer cells, 1.0E+7 cells)','1.0E+6 PFU at day 5','NA','Reduction in tumor volume to 1400 cubic millimeter compared to control 3600 cubic millimeter after 20 days','Intratumoral (intraperitoneally for etoposide)','NA','NA','NA','26515462'),
  ('OV_132','Adenovirus','Ad5GS3','DNA','Adenoviridae','E1B55K-deleted mutant driven by the MDR1 promoter','No','Virus in combination with etoposide - 2mg/kg daily from day 5 to day 8','No','NA','NA','NA','NA','NA','NA','NA','NA','Male NOD/SCID mice (subcutaneously injected A549 lung cancer cells, 1.0E+7 cells)','1.0E+6 PFU at day 5','NA','Reduction in tumor volume to 500 cubic millimeter compared to control 3600 cubic millimeter after 20 days','Intratumoral (intraperitoneally for etoposide)','NA','NA','NA','26515462'),
  ('OV_133','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_134','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_135','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','25% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_136','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','16% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_137','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_138','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','5% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_139','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','20% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_140','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','32% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_141','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','3% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_142','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','10% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_143','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','30% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_144','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','32% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_145','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','15% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_146','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','10% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_147','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','33% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_148','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','51% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_149','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','20% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_150','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','26% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_151','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','49% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_152','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','98% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_153','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','25% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_154','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','40% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_155','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','54% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_156','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','58% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_157','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','28% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_158','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','45% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_159','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','50% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_160','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','58% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_161','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','30% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_162','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','40% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_163','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 2 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','50% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_164','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubacin - 5 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','70% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_165','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁷ MOI','5% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_166','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁷ MOI','10% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_167','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁷ MOI','10% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_168','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','9% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_169','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','6% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_170','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁶ MOI','3% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_171','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','15% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_172','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','10% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_173','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁵ MOI','5% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_174','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','40% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_175','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','44% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_176','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻⁴ MOI','43% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_177','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','49% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_178','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','46% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_179','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻³ MOI','42% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_180','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','51% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_181','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_182','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻² MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_183','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','51% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_184','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_185','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3⁻¹ MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_186','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','51% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_187','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_188','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','1 MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_189','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','54% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_190','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 1 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','52% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_191','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with CI994 - 3 micromolar starting at 14 hours before infection','No','NA','Human glioblastoma astrocytoma cell line','U251','NA','NA','LDH cytotoxicity assay','3 MOI','60% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26524593'),
  ('OV_192','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Female athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells','5.0E+5 PFU (on 5 day) in total 8 mice','NA','40% mice survived on 28th day','Intratumorally','NA','NA','NA','26524593'),
  ('OV_193','Herpes simplex virus','rQNestin34.5','DNA','Herpesviridae','Deletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter','No','Virus in combination with tubastatin A (TA) at a dose of 1.3 mg per kg body weight (4, 5, 6, 7 and 8 days after tumor implantation)','No','NA','NA','NA','NA','NA','NA','NA','NA','Female athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells','5.0E+5 PFU (on 5 day) in total 8 mice','NA','80% mice survived on 28th day','Intratumorally','NA','NA','NA','26524593'),
  ('OV_194','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 173','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','90% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_195','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 173','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','80% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_196','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 173','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','30% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_197','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 31','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','10% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_198','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 31','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_199','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 31','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','1% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_200','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 35','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','52% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_201','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 35','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','25% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_202','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 35','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','10% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_203','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 36','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','55% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_204','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 36','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','32% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_205','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 36','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_206','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 37','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','55% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_207','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 37','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','32% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_208','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 37','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_209','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 47','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','48% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_210','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 47','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','10% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_211','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 47','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','4% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_212','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 56','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','80% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_213','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 56','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','52% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_214','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 56','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','18% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_215','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 76','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','90% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_216','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 76','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','60% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_217','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 76','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','20% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_218','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 96','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','30% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_219','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 96','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','12% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_220','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 96','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','4% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_221','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 152','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','49% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_222','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 152','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','25% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_223','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 152','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','8% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_224','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 225','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','30% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_225','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 225','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','16% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_226','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 225','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_227','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 13','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','50% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_228','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 13','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','25% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_229','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 13','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','4% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_230','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 34','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','60% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_231','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 34','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','30% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_232','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 34','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_233','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 122','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','75% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_234','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 122','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','25% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_235','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 122','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','4% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_236','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 11','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','75% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_237','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 11','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','60% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_238','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 11','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','32% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_239','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 163','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','75% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_240','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 163','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','40% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_241','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 163','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','10% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_242','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 4','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','85% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_243','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 4','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','78% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_244','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 4','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','35% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_245','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 45','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','110% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_246','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 45','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','90% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_247','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 45','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','10% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_248','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 52','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','100% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_249','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 52','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','95% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_250','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 52','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','70% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_251','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 61','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','80% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_252','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 61','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','50% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_253','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 61','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','12% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_254','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 95','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','42% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_255','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 95','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','22% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_256','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 95','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','8% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_257','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 150','Desnity of 5000 cells per well','NA','UptiBlue assay','0.1 MOI','40% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_258','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 150','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','30% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_259','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','Yes','No','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 150','Desnity of 5000 cells per well','NA','UptiBlue assay','10 MOI','10% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_260','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 4','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','90% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_261','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 31','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_262','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 35','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','8% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_263','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 37','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','25% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_264','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 152','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_265','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 13','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','5% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_266','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 11','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','49% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_267','Measles virus','Schwarz and Edmonston MV strain','RNA','Paramyxoviridae','None','No','Virus in combination with anti-CD46 blocking mAb - 10μg/mL added 30 minutes before adding virus','No','NA','Malignant pleural mesothelioma (MPM) cell line','Meso 163','Desnity of 5000 cells per well','NA','UptiBlue assay','1 MOI','45% cancer cell viability on 9th day (cell viability as percentage compared to non-infected cells)','No','No','NA','No response','NA','NA','NA','NA','26539644'),
  ('OV_268','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','20 MOI','92% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_269','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','50 MOI','95% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_270','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','100 MOI','92% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_271','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','90% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_272','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','200 MOI','88% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_273','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','92% cancer cell viability at 24 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_274','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','85% cancer cell viability at 48 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_275','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','90% cancer cell viability at 96 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_276','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','50 MOI','90% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_277','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','100 MOI','90% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_278','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','85% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_279','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','83% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_280','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','92% cancer cell viability at 24 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_281','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','94% cancer cell viability at 48 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_282','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','86% cancer cell viability at 96 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_283','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','20 MOI','88% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_284','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','50 MOI','75% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_285','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','100 MOI','77% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_286','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','74% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_287','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','200 MOI','70% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_288','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','90% cancer cell viability at 24 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_289','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','83% cancer cell viability at 48 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_290','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','71% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_291','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','50 MOI','91% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_292','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','100 MOI','85% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_293','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','65% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_294','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','56% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_295','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','92% cancer cell viability at 24 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_296','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','81% cancer cell viability at 48 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_297','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','61% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_298','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','50 MOI','78% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_299','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','No','Virus combined with recombinant human CD47 Fc chimera (rhCD47-Fc) - 1μg/mL','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','50 MOI','82% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_300','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','No','Virus combined with recombinant human CD47 Fc chimera (rhCD47-Fc) - 5μg/mL','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','50 MOI','96% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_301','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','100% cancer cell viability at 48 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_302','Adenovirus','Ad.IL3','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-IL3 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','90% cancer cell viability at 48 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_303','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','80% cancer cell viability at 48 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_304','Adenovirus','Ad.IL3','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-IL3 expression cassette','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','100% cancer cell viability at 72 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_305','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','20 MOI','92% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_306','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','50 MOI','65% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_307','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','100 MOI','58% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_308','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','150 MOI','52% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_309','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','K562','2.0E+4 cells per well','NA','MTT assay','200 MOI','44% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_310','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','50 MOI','82% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_311','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','100 MOI','58% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_312','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','150 MOI','52% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_313','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Leukemia cell line','HL-60','2.0E+4 cells per well','NA','MTT assay','200 MOI','38% cancer cell viability at 72 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_314','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','0.5 MOI','28% cancer cell viability at 96 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_315','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','0.5 MOI','78% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_316','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','0.5 MOI','24% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_317','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','1 MOI','24% cancer cell viability at 96 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_318','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','1 MOI','57% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_319','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','1 MOI','18% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_320','Adenovirus','Ad.sp-E1A','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP)','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','2 MOI','22% cancer cell viability at 96 hours','No','No','NA','No response','NA','NA','NA','NA','26554307'),
  ('OV_321','Adenovirus','Ad.4N1','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','2 MOI','45% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_322','Adenovirus','Ad.4N1-IL24','DNA','Adenoviridae','Viral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes','Yes','No','No','ATCC','Human lung cancer cell line','A549','NA','NA','MTT assay','2 MOI','11% cancer cell viability at 96 hours','No','No','NA','No response','NA','Induces apoptosis by upregulating Bax and activated caspase 3 levels','Induces expression of IL-24','NA','26554307'),
  ('OV_323','Canine parvovirus','CPV2.NS1','DNA','Paroviridae','CPV genome expressing non-structural protein (NS1)','Yes','No','No','NCCS (National Centre for Cell Science, Pune, India)','Human cervical cancer cell line','HeLa','density of E+4 to E+5 cells/well in 120 microlitres of culture medium','NA','LDH assay','NA','9% cancer cell death at 24 hours','No','No','NA','No response','NA','Apoptosis is induced via mitochondrial depolarization, release of cytochrome-c and activation of caspase 9','NA','NA','26555166'),
  ('OV_324','Canine parvovirus','CPV2.NS1','DNA','Paroviridae','CPV genome expressing non-structural protein (NS1)','Yes','No','No','NCCS (National Centre for Cell Science, Pune, India)','Human cervical cancer cell line','HeLa','density of E+4 to E+5 cells/well in 120 microlitres of culture medium','NA','LDH assay','NA','18% cancer cell death at 48 hours','No','No','NA','No response','NA','Apoptosis is induced via mitochondrial depolarization, release of cytochrome-c and activation of caspase 9','NA','NA','26555166'),
  ('OV_325','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H-1299','2.5E+4 cells per well','NA','Crystal violet staining','1 MOI','98% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_326','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','Crystal violet staining','1 MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_327','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','Crystal violet staining','1 MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_328','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','Crystal violet staining','1 MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_329','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H-1299','2.5E+4 cells per well','NA','Crystal violet staining','2.5 MOI','98% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_330','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','Crystal violet staining','2.5 MOI','10% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_331','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','Crystal violet staining','2.5 MOI','2% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_332','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','Crystal violet staining','2.5 MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_333','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H-1299','2.5E+4 cells per well','NA','Crystal violet staining','5 MOI','98% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_334','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','Crystal violet staining','5 MOI','92% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_335','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','Crystal violet staining','5 MOI','3% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_336','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','Crystal violet staining','5 MOI','1% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_337','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H-1299','2.5E+4 cells per well','NA','Crystal violet staining','10 MOI','99% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_338','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','Crystal violet staining','10 MOI','92% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_339','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','Crystal violet staining','10 MOI','20% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_340','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','Crystal violet staining','10 MOI','2% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_341','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H-1299','2.5E+4 cells per well','NA','Crystal violet staining','20 MOI','100% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_342','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','Crystal violet staining','20 MOI','100% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_343','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','Crystal violet staining','20 MOI','80% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_344','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','Crystal violet staining','20 MOI','45% cancer cell death','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_345','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','58% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_346','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','MTT assay','10 MOI','62% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_347','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','MTT assay','10 MOI','74% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_348','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) - 0.6 mM','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','2.5 MOI','18% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy','NA','NA','26561948'),
  ('OV_349','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) - 0.75 mM','No','ATCC','Human lung cancer cell line','H441','2.5E+4 cells per well','NA','MTT assay','20 MOI','22% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy','NA','NA','26561948'),
  ('OV_350','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) - 1 mM','No','ATCC','Human lung cancer cell line','Calu1','2.5E+4 cells per well','NA','MTT assay','10 MOI','12% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy','NA','NA','26561948'),
  ('OV_351','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','49% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_352','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','26% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26561948'),
  ('OV_353','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) and 3-MA at -0.75 mM and 10 mM concentration, respectively','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','62% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy (Autophagy effect slightly inhibited by 3-MA)','NA','NA','26561948'),
  ('OV_354','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) and 3-MA at -0.75 mM and 10 mM concentration, respectively','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','44% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy (Autophagy effect slightly inhibited by 3-MA)','NA','NA','26561948'),
  ('OV_355','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) and BAF-A1 at -0.75 mM and 10 nM concentration, respectively','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','65% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy (Autophagy effect slightly inhibited by Baf-A1)','NA','NA','26561948'),
  ('OV_356','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) and BAF-A1 at -0.75 mM and 10 nM concentration, respectively','No','ATCC','Human lung cancer cell line','A549','2.5E+4 cells per well','NA','MTT assay','10 MOI','47% cancer cell viability','No','No','NA','No response','NA','JNK activation induces autophagy (Autophagy effect slightly inhibited by Baf-A1)','NA','NA','26561948'),
  ('OV_357','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)','1.0E+9 pfu (every 3 days for at total 4 treatments)','NA','41% smaller tumor size compared to the negative control virus AdLacZ','Intratumorally','NA','NA','NA','26561948'),
  ('OV_358','Adenovirus','Adhz60','DNA','Adenoviridae','E1b-deleted mutant','No','Virus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)','1.0E+9 pfu (every 3 days for at total 4 treatments)','NA','70% smaller tumor size compared to the negative control virus AdLacZ','Intratumorally','JNK activation induces autophagy','NA','NA','26561948'),
  ('OV_359','Adenovirus','AdLacZ','DNA','Adenoviridae','E1/E3-deleted mutant','No','Virus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)','1.0E+9 pfu (every 3 days for at total 4 treatments)','NA','30% smaller tumor size compared to the negative control virus AdLacZ','Intratumorally','JNK activation induces autophagy','NA','NA','26561948'),
  ('OV_360','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHLA-20','4000 cells per well','NA','MTS cell survival assay','0.0001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_361','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHP-134','4000 cells per well','NA','MTS cell survival assay','0.0001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_362','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-AS','4000 cells per well','NA','MTS cell survival assay','0.0001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_363','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-BE(2)','4000 cells per well','NA','MTS cell survival assay','0.0001 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_364','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHLA-20','4000 cells per well','NA','MTS cell survival assay','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_365','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHP-134','4000 cells per well','NA','MTS cell survival assay','0.01 MOI','18% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_366','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-AS','4000 cells per well','NA','MTS cell survival assay','0.01 MOI','76% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_367','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-BE(2)','4000 cells per well','NA','MTS cell survival assay','0.01 MOI','100% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_368','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHLA-20','4000 cells per well','NA','MTS cell survival assay','0.1 MOI','98% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_369','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHP-134','4000 cells per well','NA','MTS cell survival assay','0.1 MOI','1% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_370','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-AS','4000 cells per well','NA','MTS cell survival assay','0.1 MOI','26% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_371','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-BE(2)','4000 cells per well','NA','MTS cell survival assay','0.1 MOI','58% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_372','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHLA-20','4000 cells per well','NA','MTS cell survival assay','1 MOI','72% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_373','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','CHP-134','4000 cells per well','NA','MTS cell survival assay','1 MOI','1% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_374','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-AS','4000 cells per well','NA','MTS cell survival assay','1 MOI','15% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_375','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','ATCC or from the Pediatric Preclinical Testing Program (PPTP)','Human neuroblastoma cell line','SK-N-BE(2)','4000 cells per well','NA','MTS cell survival assay','1 MOI','18% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','26583803'),
  ('OV_376','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic nude mice (subcutaneously xenografted with CHLA-20)','1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)','NA','42% mice survived','Intratumorally','NA','NA','NA','26583803'),
  ('OV_377','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic nude mice (subcutaneously xenografted with CHP-123)','1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)','NA','63% mice survived','Intratumorally','NA','NA','NA','26583803'),
  ('OV_378','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic nude mice (subcutaneously xenografted with SK-N-AS)','1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)','NA','0% mice survived','Intratumorally','NA','NA','NA','26583803'),
  ('OV_379','Herpes simplex virus','Seprehvir (HSV1716)','DNA','Herpesviridae','Δγ134.5 attenuated virus mutant','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic nude mice (subcutaneously xenografted with SK-N-BE(2))','1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)','NA','18% mice survived','Intratumorally','NA','NA','NA','26583803'),
  ('OV_380','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMCH-1','3.0E+3 cells per well','NA','Dojindo cell counting kit','0.01 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_381','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMC-1','1.0E+4 cells per well','NA','Dojindo cell counting kit','0.01 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_382','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMBC','1.0E+4 cells per well','NA','Dojindo cell counting kit','0.01 MOI','90% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_383','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMCH-1','3.0E+3 cells per well','NA','Dojindo cell counting kit','0.1 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_384','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMC-1','1.0E+4 cells per well','NA','Dojindo cell counting kit','0.1 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_385','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMBC','1.0E+4 cells per well','NA','Dojindo cell counting kit','0.1 MOI','48% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_386','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMCH-1','3.0E+3 cells per well','NA','Dojindo cell counting kit','1 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_387','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMC-1','1.0E+4 cells per well','NA','Dojindo cell counting kit','1 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_388','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMBC','1.0E+4 cells per well','NA','Dojindo cell counting kit','1 MOI','20% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_389','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMCH-1','3.0E+3 cells per well','NA','Dojindo cell counting kit','5 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_390','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMC-1','1.0E+4 cells per well','NA','Dojindo cell counting kit','5 MOI','13% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_391','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','ATCC','Human cholangiocarcinoma cell line','KMBC','1.0E+4 cells per well','NA','Dojindo cell counting kit','5 MOI','20% cancer cell viability on 7 day','No','No','NA','No response','NA','NA','NA','NA','26584530'),
  ('OV_392','Vaccinia virus','GLV-1h68','DNA','Poxviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Homozygous athymic female nude mice (subcutaneously injected with KMC-1 cells suspended in 50 μl Matrigel)','1.0E+7 PFU','NA','Reduction in tumor volume to 30 cubic millimeter compared to control 200 cubic millimeter after 15 days','Intratumorally','NA','NA','NA','26584530'),
  ('OV_393','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','Yes','No','No','ATCC','Human malignant melanoma cell lines','A2058','NA','NA','Trypan blue staining','1 MOI','50% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_394','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','No','Viral strain in combination with SP600125 (100 μM)','No','ATCC','Human malignant melanoma cell lines','A2058','NA','NA','Trypan blue staining','1 MOI','35% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_395','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','No','Viral strain in combination with 3-MA (5 mM)','No','ATCC','Human malignant melanoma cell lines','A2058','NA','NA','Trypan blue staining','1 MOI','38% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_396','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','No','Viral strain in combination with z-YVAD- fmk (100 μM)','No','ATCC','Human malignant melanoma cell lines','A2058','NA','NA','Trypan blue staining','1 MOI','44% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_397','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','Yes','No','No','ATCC','Human malignant melanoma cell lines','A375','NA','NA','Trypan blue staining','1 MOI','55% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_398','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','No','Viral strain in combination with SP600125 (100 μM)','No','ATCC','Human malignant melanoma cell lines','A375','NA','NA','Trypan blue staining','1 MOI','35% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_399','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','No','Viral strain in combination with 3-MA (5 mM)','No','ATCC','Human malignant melanoma cell lines','A375','NA','NA','Trypan blue staining','1 MOI','44% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_400','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','No','Viral strain in combination with z-YVAD- fmk (100 μM)','No','ATCC','Human malignant melanoma cell lines','A375','NA','NA','Trypan blue staining','1 MOI','42% cancer cell death at 48 hours after post infection','No','No','NA','No response','NA','Induces JNK/c-Jun, autophagy and pyroptosis activation','ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes','NA','26602205'),
  ('OV_401','Herpes simplex virus','ICP10PK','DNA','Herpesviridae','Deletion mutant with R1 domain poorly functional in HSV-1','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Xenograft male BALB/c nu/nu mice (subcutaneously injected with 1.0E+7  A3755 cells in 100 μl)','100 μl; 1.0E+6 PFU on day 7','NA','On day 29 , tumor growth ratio reached 2 as compared to 13 (tumour growth ratio - dividing each tumour volume measured over time by the initial tumour volume on day 7)','Intratumorally','NA','MICA and TNF-alpha expressions are upregulated','NA','26602205'),
  ('OV_402','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','110% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_403','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','40% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_404','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','118% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_405','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','39% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_406','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','98% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_407','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','42% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_408','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','78% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_409','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','40% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_410','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','30% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_411','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','38% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_412','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_413','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','38% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_414','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','35% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_415','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','35% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_416','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','24% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_417','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_418','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_419','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','21% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_420','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_421','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_422','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','12% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_423','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_424','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','8% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_425','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','Yes','No','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','12% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_426','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','110% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_427','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','50% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_428','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','130% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_429','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','50% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_430','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','116% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_431','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','51% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_432','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','100% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_433','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','40% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_434','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','50% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_435','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','38% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_436','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human cervical squamous cell carcinoma cell line','OV-4','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_437','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovarian serous adenocarcinoma cell line','OVCAR3','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','40% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_438','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','88% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_439','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','46% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_440','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','62% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_441','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_442','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','26% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_443','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','22% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_444','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','24% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_445','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_446','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_447','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_448','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_449','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','Yes','No','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_450','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','90% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_451','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','58% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_452','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','74% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_453','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','22% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_454','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','28% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_455','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_456','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_457','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_458','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_459','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_460','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_461','Adenovirus','CRAd-ING4 (Ad5/3Δ24cmvING4)','DNA','Adenoviridae','Viral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','No','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_462','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','56% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_463','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','58% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_464','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','24% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_465','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_466','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_467','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_468','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_469','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_470','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_471','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_472','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_473','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene)','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','12% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_474','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','30% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_475','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','0.4 MOI','38% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_476','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','22% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_477','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','1 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_478','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_479','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','4 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_480','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_481','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','11 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_482','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_483','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','33 MOI','16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_484','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3ip.1 OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_485','Adenovirus','CRAd-IL24 (Ad5/3Δ24cmvIL24)','DNA','Adenoviridae','Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).','No','Viral starin in combination with ING4','IL-24 gene incorporated in place of the deleted E3B region','ATCC','Human ovary cancer cell line','SKOV3luc OvCa','3.0E+5 to 5.0E+5 cells per well','Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells','MTS-based Cell Proliferation Assay (Promega)','100 MOI','14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)','No','No','NA','No response','NA','NA','NA','NA','27349517'),
  ('OV_486','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','1 MOI','90% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_487','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','102% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_488','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','108% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_489','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','1 MOI','98% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_490','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','5 MOI','76% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_491','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','98% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_492','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','102% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_493','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','5 MOI','85% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_494','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','10 MOI','58% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_495','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','96% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_496','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','100% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_497','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','10 MOI','96% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_498','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','50 MOI','20% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_499','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','80% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_500','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','37% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_501','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','50 MOI','78% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_502','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','100 MOI','10% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_503','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','56% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_504','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','12% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_505','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','100 MOI','60% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_506','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','1 MOI','98% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_507','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','99% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_508','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','92% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_509','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','1 MOI','90% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_510','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','5 MOI','76% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_511','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','84% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_512','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','73% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_513','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','5 MOI','88% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_514','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','10 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_515','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','65% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_516','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_517','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','10 MOI','70% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_518','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','50 MOI','30% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_519','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_520','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_521','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','50 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_522','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','100 MOI','16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_523','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','36% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_524','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_525','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','100 MOI','32% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_526','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','1 MOI','78% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_527','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','83% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_528','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','79% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_529','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','1 MOI','66% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_530','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','5 MOI','62% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_531','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','77% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_532','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','69% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_533','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','5 MOI','58% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_534','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','10 MOI','44% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_535','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','60% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_536','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_537','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','10 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_538','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','50 MOI','30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_539','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','45% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_540','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_541','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','50 MOI','38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_542','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','100 MOI','12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_543','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','35% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_544','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_545','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','100 MOI','23% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_546','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','1 MOI','50% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_547','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','65% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_548','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','1 MOI','50% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_549','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','1 MOI','16% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_550','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','5 MOI','42% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_551','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','60% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_552','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','5 MOI','44% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_553','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','5 MOI','16% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_554','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','10 MOI','30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_555','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_556','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','10 MOI','30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_557','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','10 MOI','16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_558','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','50 MOI','21% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_559','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_560','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','50 MOI','22% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_561','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','50 MOI','16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_562','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','SaOS-2','1.0E+3 cells per well','NA','XTT assay','100 MOI','10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_563','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','DS Pharma Biomedical','Human osteosarcoma cell line','MNNG/HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','25% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis','NA','NA','27356624'),
  ('OV_564','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','Dr. Satoru Kyo (Shimane University, Izumo, Japan)','Human osteosarcoma cell line','HOS','1.0E+3 cells per well','NA','XTT assay','100 MOI','10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_565','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )','No','ATCC','Human osteosarcoma cell line','143-B','1.0E+3 cells per well','NA','XTT assay','100 MOI','12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs','No','No','NA','No response','NA','NA','NA','NA','27356624'),
  ('OV_566','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Female BALB/c nu/nu mice inoculated subcutaneously with MNNG/HOS-Luc cells (5.0E+6 cells per site)','5.0E+7 PFU','NA','Proliferating tumor cells expressing ki67 get reduced from 550 cells to 250 cells','Direct injection','NA','NA','NA','27356624'),
  ('OV_567','Adenovirus','OBP-301 (telomelysin)','DNA','Adenoviridae','Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells','No','Viral strain in combination with cisplatin (CDDP, 4 mg/kg body weight ) and doxorubicin (DOX, 2 mg/kg body weight )[drugs were given intraperitoneally]','No','NA','NA','NA','NA','NA','NA','NA','NA','Female BALB/c nu/nu mice inoculated subcutaneously with MNNG/HOS-Luc cells (5.0E+6 cells per site)','5.0E+7 PFU','NA','Proliferating tumor cells expressing ki67 get reduced from 550 cells to 75 cells','Direct injection','NA','NA','NA','27356624'),
  ('OV_568','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with PKA catalytic subunit siRNA and scramble siRNA (siPKA-1)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','NA','MTT assay','10 PFU/cell','62% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','NA','NA','27374176'),
  ('OV_569','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with PKA catalytic subunit siRNA and scramble siRNA (siPKA-2)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','NA','MTT assay','10 PFU/cell','57% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','NA','NA','27374176'),
  ('OV_570','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with PKA catalytic subunit siRNA and scramble siRNA (siPKA-3)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','NA','MTT assay','10 PFU/cell','65% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','NA','NA','27374176'),
  ('OV_571','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','NA','MTT assay','10 PFU/cell','50% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_572','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','0.001 PFU/cell','70% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_573','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','0.001 PFU/cell','100% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_574','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','0.01 PFU/cell','39% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_575','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','0.01 PFU/cell','100% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_576','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','0.1 PFU/cell','22% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_577','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','0.1 PFU/cell','92% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_578','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','1 PFU/cell','20% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_579','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','1 PFU/cell','80% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_580','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','20% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_581','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','10 PFU/cell','75% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_582','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','0.001 PFU/cell','86% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_583','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','0.001 PFU/cell','100% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_584','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','0.01 PFU/cell','80% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_585','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','0.01 PFU/cell','100% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_586','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','0.1 PFU/cell','70% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_587','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','0.1 PFU/cell','100% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_588','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','1 PFU/cell','38% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_589','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','1 PFU/cell','90% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_590','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89(10 μM) for 1 hour','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','25% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_591','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','Non toxic to human immortalized liver cell line L-02','MTT assay','10 PFU/cell','80% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_592','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1001)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','100% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_593','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1002)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','70% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_594','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1003)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','90% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','NA','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_595','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1001) and with H89(10 μM)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','60% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_596','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1002) and with H89(10 μM)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','45% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_597','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1003) and with H89(10 μM)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','Very small toxicity towards human immortalized liver cell line L-02','MTT assay','10 PFU/cell','75% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','JNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_598','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with ESI-09 and with H89(10 μM)','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','NA','MTT assay','0.1 PFU/cell','60% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','ESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_599','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with ESI-09','No','ATCC','Human colorectal carcinoma cell line','HCT-116','4000 cells per well','NA','MTT assay','0.1 PFU/cell','80% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','ESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_600','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with ESI-09 and with H89(10 μM)','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','NA','MTT assay','0.1 PFU/cell','75% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','ESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.','M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89','NA','27374176'),
  ('OV_601','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with ESI-09','No','ATCC','Human pancreatic ductal adenocarcinoma cell line','Capan-1','4000 cells per well','NA','MTT assay','0.1 PFU/cell','82% cancer cell viability at 72 hours post-infection','No','No','NA','No response','NA','ESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.','M1 upregulated transcriptional ISGs (329 shown here)','NA','27374176'),
  ('OV_602','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89 (10 mg/kg/d), injected intraperitoneally','No','NA','NA','NA','NA','NA','NA','NA','NA','Female BALB/c-nu/nu mice inoculated subcutaneously with HCT-116, 5.0E+6 cells per mouse','3.0E+7 PFU/d','NA','Reduction in tumor volume to 0.2 cubic centimeter compared to control 1cubic centimeter after 27 days','intravenously','Activates Caspase-3','NA','NA','27374176'),
  ('OV_603','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Female BALB/c-nu/nu mice inoculated subcutaneously with HCT-116, 5.0E+6 cells per mouse','3.0E+7 PFU/d','NA','Reduction in tumor volume to 0.76 cubic centimeter compared to control 1cubic centimeter after 27 days','intravenously','Activates Caspase-3 (very small)','NA','NA','27374176'),
  ('OV_604','Alphavirus','M1','RNA','Togaviridae','None','No','Viral strain in combination with H89 (10 mg/kg/d), injected intraperitoneally','No','NA','NA','NA','NA','NA','NA','NA','NA','Female BALB/c-nu/nu mice inoculated subcutaneously with Capan-1, 3.0E+6 cells per mouse','3.0E+7 PFU/d','NA','Reduction in tumor volume to 0.1 cubic centimeter compared to control 1cubic centimeter after 23 days','intravenously','Activates Caspase-3','NA','NA','27374176'),
  ('OV_605','Alphavirus','M1','RNA','Togaviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Female BALB/c-nu/nu mice inoculated subcutaneously with Capan-1, 3.0E+6 cells per mouse','3.0E+7 PFU/d','NA','Reduction in tumor volume to 0.2 cubic centimeter compared to control 1cubic centimeter after 23 days','intravenously','Activates Caspase-3 (very small)','NA','NA','27374176'),
  ('OV_606','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','Key Laboratory of Zoonosis, Jilin University','Human prostate cancer cell line','PC-3M','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','70% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_607','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human cervical cancer cell','HeLa','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','85% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_608','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human bone osteosarcoma epithelial cell line','U2OS (telomerase-negative)','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','96% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_609','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','Key Laboratory of Zoonosis, Jilin University','Human prostate cancer cell line','PC-3M','1.0E+5 cells per well','NA','MTT assay','1 MOI','40% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_610','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human cervical cancer cell','HeLa','1.0E+5 cells per well','NA','MTT assay','1 MOI','37% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_611','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human bone osteosarcoma epithelial cell line','U2OS (telomerase-negative)','1.0E+5 cells per well','NA','MTT assay','1 MOI','94% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_612','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','Key Laboratory of Zoonosis, Jilin University','Human prostate cancer cell line','PC-3M','1.0E+5 cells per well','NA','MTT assay','10 MOI','18% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_613','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human cervical cancer cell','HeLa','1.0E+5 cells per well','NA','MTT assay','10 MOI','8% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_614','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human bone osteosarcoma epithelial cell line','U2OS (telomerase-negative)','1.0E+5 cells per well','NA','MTT assay','10 MOI','92% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_615','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','Key Laboratory of Zoonosis, Jilin University','Human prostate cancer cell line','PC-3M','1.0E+5 cells per well','NA','MTT assay','50 MOI','10% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_616','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human cervical cancer cell','HeLa','1.0E+5 cells per well','NA','MTT assay','50 MOI','5% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_617','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','ATCC','Human bone osteosarcoma epithelial cell line','U2OS (telomerase-negative)','1.0E+5 cells per well','NA','MTT assay','50 MOI','90% cancer cell viability','No','No','NA','No response','NA','NA','NA','NA','27380620'),
  ('OV_618','Adenovirus','CRAd-CCL21-IL15','DNA','Adenoviridae','Insertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells','Yes','No','IL-15','NA','NA','NA','NA','NA','NA','NA','NA','SCID mice were injected intradermally 4.0E+6 Caco-2 cells','4.0E+8 IFU','NA','Reduction in tumor volume to 550 cubic millimeter compared to control 3100 cubic millimeter after 40 days','Intratumoral','NA','NA','NA','27380620'),
  ('OV_619','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','77% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_620','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','77% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_621','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','52% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_622','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','48% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_623','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','1 MOI','40% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_624','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','60% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_625','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','50% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_626','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','48% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_627','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','40% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_628','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','1 MOI','38% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_629','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','120% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_630','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','110% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_631','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','60% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_632','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','40% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_633','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','1 MOI','30% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_634','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','110% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_635','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','70% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_636','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','58% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_637','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','25% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_638','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','1 MOI','25% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_639','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','105% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_640','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','107% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_641','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','90% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_642','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','70% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_643','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','1 MOI','61% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_644','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','90% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_645','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','93% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_646','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','87% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_647','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','58% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_648','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','1 MOI','59% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_649','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','111% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_650','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','102% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_651','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','98% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_652','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','75% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_653','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','1 MOI','50% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_654','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','106% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_655','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','95% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_656','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','89% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_657','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','39% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_658','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','1 MOI','40% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_659','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','100% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_660','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','96% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_661','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','92% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_662','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','92% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_663','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','1 MOI','90% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_664','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','88% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_665','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','94% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_666','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','90% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_667','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','91% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_668','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (antagonism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','1 MOI','88% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_669','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','98% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_670','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','78% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_671','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','60% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_672','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','20% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_673','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 3 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','1 MOI','12% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_674','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','70% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_675','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','60% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_676','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','17% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_677','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','8% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_678','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 5 Gy (synergism)','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','1 MOI','8% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_679','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','120% cancer cell viability (calculated as relative to mock-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_680','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','105% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_681','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','100% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_682','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','70% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_683','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','A375','1.0E+5 cells per well','NA','MTT assay','1 MOI','50% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_684','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','120% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_685','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','105% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_686','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','77% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_687','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','50% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_688','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','DO4','1.0E+5 cells per well','NA','MTT assay','1 MOI','30% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_689','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','120% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_690','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','126% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_691','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','92% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_692','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','72% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_693','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human melanoma cell line','MeWo','1.0E+5 cells per well','NA','MTT assay','1 MOI','61% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_694','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','120% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_695','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','105% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_696','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','110% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_697','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','99% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_698','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human malignant melanoma cell line','Mel624','1.0E+5 cells per well','NA','MTT assay','1 MOI','70% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_699','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','108% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_700','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','90% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_701','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','100% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_702','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','85% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_703','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','WM1791c','1.0E+5 cells per well','NA','MTT assay','1 MOI','92% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_704','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.001 MOI','110% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_705','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.01 MOI','92% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_706','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.1 MOI','70% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_707','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','0.5 MOI','25% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_708','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','Prof. Richard Marais lab','Human cutaneous melanoma cell line','PMWK','1.0E+5 cells per well','NA','MTT assay','1 MOI','19% cancer cell viability (calculated as relative to non-infected group)','No','No','NA','No response','NA','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3','NA','NA','27384486'),
  ('OV_709','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Xenograft female CD1 nude mice subcutaneously injected with 3.0E+6  A375 cells','1.0E+6 pfu/ml','NA','%volume change is 400 as compared to control 700 after 40 days','Intratumoral','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 3','NA','NA','27384486'),
  ('OV_710','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','No','Viral strain in combination with radiation, 2 Gy for 3 cycles','No','NA','NA','NA','NA','NA','NA','NA','NA','Xenograft female CD1 nude mice subcutaneously injected with 3.0E+6  A375 cells','1.0E+6 pfu/ml','NA','%volume change is 100 as compared to control 700 after 40 days','Intratumoral','Down-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 3','NA','NA','27384486'),
  ('OV_711','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','C57Bl/6j mice subcutaneously injected with 5.0E+5 B16F10 cells','1.0E+7 PFU to 1.0E+9 PFU for three weeks','NA','77% survived till 30 days (Reduction in tumor volume to 0.15 cubic centimeter compared to control 0.9 cubic centimeter after 15 days)','intravenously','NA','Up-regulation of IL-12, IL-5, IL-10, TNF-alpha','NA','27412241'),
  ('OV_712','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','C57Bl/6j mice subcutaneously injected with 2.0E+5 LLC cells','1.0E+7 PFU to 1.0E+9 PFU for three weeks','NA','80% survived till 40 days (Reduction in tumor volume to 0.3 cubic centimeter compared to control 1.0 cubic centimeter after 20 days)','intravenously','NA','Up-regulation of IFN-gamma','NA','27412241'),
  ('OV_713','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','C57Bl/6j mice subcutaneously injected with 5.0E+5 B16F10 cells (vaccinated with cell-based Reovirus vaccine 8–12 weeks prior to day 0)','1.0E+7 PFU to 1.0E+9 PFU for three weeks','NA','100% survived till 150 days (Reduction in tumor volume to 0.0 cubic centimeter compared to control 1.4 cubic centimeter after 16 days)','intravenously','NA','Up-regulation of IL-12, IL-5, IL-10, TNF-alpha','NA','27412241'),
  ('OV_714','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','C57Bl/6j mice subcutaneously injected with 2.0E+5 LLC cells (vaccinated with cell-based Reovirus vaccine 8–12 weeks prior to day 0)','1.0E+7 PFU to 1.0E+9 PFU for three weeks','NA','100% survived till 200 days (Reduction in tumor volume to 0.0 cubic centimeter compared to control 1.3 cubic centimeter after 11 days)','intravenously','NA','Up-regulation of IFN-gamma','NA','27412241'),
  ('OV_715','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','C57Bl/6j mice subcutaneously injected with 5.0E+5 B16F10 cells (prior single dose of cell-based reovirus vaccine for the treatment of established tumours)','2.0E+7 PFU to 1.0E+9 PFU for three weeks','NA','77% survived till 44 days (Reduction in tumor volume to 0.1 cubic centimeter compared to control 1.2 cubic centimeter after 16 days)','intravenously','NA','Up-regulation of IL-12, IL-5, IL-10, TNF-alpha','NA','27412241'),
  ('OV_716','Reovirus','RT3D (Reolysin)','RNA','Reoviridae','None','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','C57Bl/6j mice subcutaneously injected with 2.0E+5 LLC cells (prior single dose of cell-based reovirus vaccine for the treatment of established tumours)','3.0E+7 PFU to 1.0E+9 PFU for three weeks','NA','60% survived till 52 days (Reduction in tumor volume to 0.14 cubic centimeter compared to control 21 cubic centimeter after 15 days)','intravenously','NA','Up-regulation of IFN-gamma','NA','27412241'),
  ('OV_717','Avian influenza A virus','H7N3 NS1-77','RNA','Orthomyxoviridae','Mutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)','Yes','No','No','NA','Human pancreatic cancer cell line','BxPC-3','NA','NA','Immunoassay detection','0.001 MOI','130% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_718','Avian influenza A virus','H7N3 NS1-77','RNA','Orthomyxoviridae','Mutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)','Yes','No','No','NA','Human pancreatic cancer cell line','MIAPaCa-2','NA','NA','Immunoassay detection','0.001 MOI','70% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_719','Avian influenza A virus','H7N3 NS1-77','RNA','Orthomyxoviridae','Mutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)','Yes','No','No','NA','Human caucasian pancreatic adenocarcinoma','CFPAC-1','NA','NA','Immunoassay detection','0.001 MOI','111% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_720','Avian influenza A virus','H7N3 NS1-77','RNA','Orthomyxoviridae','Mutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)','Yes','No','No','NA','Human pancreas adenocarcinoma cell line','AsPC-1','NA','NA','Immunoassay detection','0.001 MOI','128% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_721','Avian influenza A virus','H7N3','RNA','Orthomyxoviridae','None','Yes','No','No','NA','Human pancreatic cancer cell line','BxPC-3','NA','NA','Immunoassay detection','0.001 MOI','148% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_722','Avian influenza A virus','H7N3','RNA','Orthomyxoviridae','None','Yes','No','No','NA','Human pancreatic cancer cell line','MIAPaCa-2','NA','NA','Immunoassay detection','0.001 MOI','90% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_723','Avian influenza A virus','H7N3','RNA','Orthomyxoviridae','None','Yes','No','No','NA','Human caucasian pancreatic adenocarcinoma','CFPAC-1','NA','NA','Immunoassay detection','0.001 MOI','130% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_724','Avian influenza A virus','H7N3','RNA','Orthomyxoviridae','None','Yes','No','No','NA','Human pancreas adenocarcinoma cell line','AsPC-1','NA','NA','Immunoassay detection','0.001 MOI','165% cancer cell death (calculated as relative to mock-infected)','No','No','NA','No response','NA','NA','Up-regulation of IFN-aplha','NA','27417501'),
  ('OV_725','Avian influenza A virus','H7N3','RNA','Orthomyxoviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','SCID-B17 female mice inoculated subcutaneously in the right flank with 100 μl of 5.0E+6 BxPC-3Luc cells','1.0E+5 PFU','NA','%volume change is 170 as compared to control 340 after 23 days','Intratumoral','NA','NA','NA','27417501'),
  ('OV_726','Avian influenza A virus','H7N3 NS1-77','RNA','Orthomyxoviridae','Mutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','SCID-B17 female mice inoculated subcutaneously in the right flank with 100 μl of 5.0E+6 BxPC-3Luc cells','1.0E+5 PFU','NA','%volume change is 90 as compared to control 340 after 23 days','Intratumoral','NA','NA','NA','27417501'),
  ('OV_727','Vaccinia virus','VV-Onco','DNA','Poxviridae','The viral thymidine kinase (TK) gene is insertionally inactivated','Yes','No','No','Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China','Human hepatocellular carcinoma cell line','MHCC97-H','5000 to 7000 cells per well','NA','MTT assay','1 MOI','70% cancer cell viability at 96 hours post-infection','No','No','NA','No response','NA','NA','NA','NA','27441866'),
  ('OV_728','Vaccinia virus','VV-Onco','DNA','Poxviridae','The viral thymidine kinase (TK) gene is insertionally inactivated','Yes','No','No','Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China','Human hepatocellular carcinoma cell line','MHCC97-H','5000 to 7000 cells per well','NA','MTT assay','10 MOI','50% cancer cell viability at 96 hours post-infection','No','No','NA','No response','NA','NA','NA','NA','27441866'),
  ('OV_729','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','10 MOI','97% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_730','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','Huh-7','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','10 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_731','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','50 MOI','52% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_732','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','Huh-7','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','50 MOI','50% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_733','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','100 MOI','33% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_734','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','Huh-7','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','100 MOI','38% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_735','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2','1.0E+4 cells per well','NA','MTT assay','10 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_736','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','Huh-7','1.0E+4 cells per well','NA','MTT assay','10 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_737','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2','1.0E+4 cells per well','NA','MTT assay','50 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_738','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','Huh-7','1.0E+4 cells per well','NA','MTT assay','50 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_739','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2','1.0E+4 cells per well','NA','MTT assay','100 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_740','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','Huh-7','1.0E+4 cells per well','NA','MTT assay','100 MOI','100% cancer cell viability on day 5','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_741','Adenovirus','AdAFPp-E1A-122','DNA','Adenoviridae','The viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with mimics','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','50 MOI','80% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_742','Adenovirus','AdAFPp-E1A-122','DNA','Adenoviridae','The viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with negative control','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','50 MOI','50% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_743','Adenovirus','AdAFPp-E1A-122','DNA','Adenoviridae','The viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with mimics','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','100 MOI','65% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_744','Adenovirus','AdAFPp-E1A-122','DNA','Adenoviridae','The viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with negative control','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','100 MOI','45% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_745','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with mimics','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','50 MOI','61% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_746','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with negative control','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','50 MOI','61% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_747','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with mimics','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','100 MOI','46% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_748','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China','Human hepatocellular carcinoma cell line','HepG2 with negative control','1.0E+4 cells per well','Slight toxicity to HL-7702 cell line','MTT assay','100 MOI','46% cancer cell viability on day 3','No','No','NA','No response','NA','NA','NA','NA','27450327'),
  ('OV_749','Adenovirus','AdAFPp-E1A','DNA','Adenoviridae','The viral mutant with E1A gene driven by AFP promoter','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','HepG2 orthotopic liver xenograft tumor in Balb/c athymic nude','NA','NA','Reduction in tumor weight to 0.2 g compared to control 0.75 g after 18 days','intravenously','NA','NA','NA','27450327'),
  ('OV_750','Adenovirus','AdAFPp-E1A-122','DNA','Adenoviridae','The viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','HepG2 orthotopic liver xenograft tumor in Balb/c athymic nude','NA','NA','Reduction in tumor weight to 0.2 g compared to control 0.75 g after 18 days','intravenously','NA','NA','NA','27450327'),
  ('OV_751','Adenovirus','AdTrack','DNA','Adenoviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','HepG2 orthotopic liver xenograft tumor in Balb/c athymic nude','NA','NA','Reduction in tumor weight to 0.85 g compared to control 0.75 g after 18 days','intravenously','NA','NA','NA','27450327'),
  ('OV_752','Adenovirus','AdAFPp-E1A-122','DNA','Adenoviridae','The viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','HepG2 subcutaneous liver xenograft tumor in Balb/c athymic nude','NA','NA','Reduction in tumor volume to 0.8 cubic centimeter compared to control 2.4 cubic centimeter after 15 days','intravenously','NA','NA','NA','27450327'),
  ('OV_753','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','90% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_754','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','58% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_755','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','41% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_756','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','36% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_757','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','25% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_758','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','90% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_759','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','60% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_760','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','49% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_761','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','36% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_762','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','30% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_763','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','99% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_764','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','76% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_765','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','64% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_766','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','60% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_767','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','52% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_768','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','80% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_769','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','60% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_770','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','50% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_771','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','46% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_772','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','40% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_773','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','80% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_774','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','65% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_775','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','55% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_776','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','46% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_777','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','39% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_778','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','88% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_779','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','60% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_780','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','50% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_781','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','39% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_782','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','38% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_783','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','90% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_784','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','57% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_785','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','30% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_786','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','11% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_787','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','9% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_788','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','90% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_789','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','45% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_790','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','34% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_791','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','11% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_792','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','8% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_793','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','99% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_794','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','60% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_795','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','49% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_796','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','35% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_797','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','30% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_798','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','80% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_799','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','40% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_800','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','32% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_801','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','25% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_802','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','HL-60','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','20% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_803','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','80% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_804','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','56% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_805','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','34% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_806','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','21% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_807','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','18% cancer cell viability at 120 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_808','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','90% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_809','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','50% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_810','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','39% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_811','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','120 MOI','21% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_812','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','BV-173','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','160 MOI','18% cancer cell viability at 96 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_813','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 40 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','50% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_814','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','42% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_815','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 40 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','64% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_816','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','50% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_817','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','80% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_818','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 240 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','76% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_819','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','64% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_820','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 240 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','10 MOI','55% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_821','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 40 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','35% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_822','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human chronic myelogenous leukemic cell line','K562','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','29% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_823','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 40 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','50% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_824','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute lymphoblastic leukemic cell line','SUP-B15','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','80 MOI','38% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_825','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','40% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_826','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 240 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human megakaryoblastic leukemic cell line','MEG-01','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','39% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_827','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 120 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','50% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_828','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 240 ng/ml','No','Gibco, Thermo Fisher Scientific, Waltham, MA, USA','Human acute promyelocytic leukemic cell line','NB4','1.0E+4 cells per well','Slight toxicity to L-02 and BJ cell line','Cell counting kit-8 (CCK-8) assay','40 MOI','42% cancer cell viability at 72 hours','No','No','NA','No response','NA','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_829','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','No','Viral strain in combination with DNR 300 μg/kg','No','NA','NA','NA','NA','NA','NA','NA','NA','Xenograft BALB/c nu/nu female mice subcutaneously injected with 1.0E+7 × 10⁷ K562 cells in a total volume of 100 μl','1.0E+9 pfu/ml','NA','Reduction in tumor volume to 20 cubic millimeter compared to control 880 cubic millimeter after 30 days','Intratumoral','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_830','Adenovirus','SG611-VSTM1','DNA','Adenoviridae','A VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Xenograft BALB/c nu/nu female mice subcutaneously injected with 1.0E+7 × 10⁷ K562 cells in a total volume of 100 μl','1.0E+9 pfu/ml','NA','Reduction in tumor volume to 80 cubic millimeter compared to control 880 cubic millimeter after 30 days','Intratumoral','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_831','Adenovirus','SG611','DNA','Adenoviridae','None','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Xenograft BALB/c nu/nu female mice subcutaneously injected with 1.0E+7 × 10⁷ K562 cells in a total volume of 100 μl','1.0E+9 pfu/ml','NA','Reduction in tumor volume to 120 cubic millimeter compared to control 880 cubic millimeter after 30 days','Intratumoral','Enhanced apoptosis activation is observed','NA','NA','27472927'),
  ('OV_832','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','Natural','colorectal cancer cell line','C18','3.0E+4 cells per well','NA','Beta galacosidase colorimetric assay','0.1 MOI','31% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10428757'),
  ('OV_833','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','Natural','colorectal cancer cell line','C29','3.0E+4 cells per well','NA','Beta galacosidase colorimetric assay','0.1 MOI','31% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10428757'),
  ('OV_834','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','Natural','colorectal cancer cell line','C85','3.0E+4 cells per well','NA','Beta galacosidase colorimetric assay','0.1 MOI','76% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10428757'),
  ('OV_835','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','Natural','colorectal cancer cell line','C86','3.0E+4 cells per well','NA','Beta galacosidase colorimetric assay','0.1 MOI','76% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10428757'),
  ('OV_836','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','Natural','Cellosaurus cell line','HCT-8','3.0E+4 cells per well','NA','Beta galacosidase colorimetric assay','0.1 MOI','76% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10428757'),
  ('OV_837','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','No','No','NA','No response','NA','NA','NA','NA','10428757'),
  ('OV_838','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic rat xenograft model for C85 cell line','1.0E+7 pfu\n','NA','No response','Direct injection','NA','NA','NA','10428757'),
  ('OV_839','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic rat xenograft model for C86 cell line','1.0E+7 pfu\n','NA','4 xenograft model shows partial reduction and 2 shows complete reduction (50% reduction)','Direct injection','NA','NA','NA','10428757'),
  ('OV_840','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Athymic rat xenograft model for HCT8 cell line','1.0E+7 pfu\n','NA','4 xenograft model shows complete reduction and 4 shows partial reduction (complete reduction)','Direct injection','NA','NA','NA','10428757'),
  ('OV_841','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant of both copies of gamma 34.5 gene','Yes','No','No','NA','NA','NA','NA','NA','NA','NA','NA','Male buffalo rat xenograft model of Morris hepatome McA-RH7777 cell','1.0E+8 pfu\n','NA','Complete reduction in tumor nodes','Portal infusion','NA','NA','NA','10428757'),
  ('OV_842','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','NA','Epithelial ovarian carcinoma','SKOV3','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.01 MOI','35% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_843','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','OVCAR3','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.01 MOI','35% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_844','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','CaOV3','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.01 MOI','35% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_845','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2780','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.01 MOI','35% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_846','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2781','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.1 MOI','75% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_847','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2782','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.1 MOI','75% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_848','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2783','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.1 MOI','75% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_849','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2784','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','0.1 MOI','75% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_850','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2784','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','1 MOI','98% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_851','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2784','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','1 MOI','98% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_852','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2784','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','1 MOI','98% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_853','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','Epithelial ovarian carcinoma','A2784','3.0E+3 cells per well','Minimal cytotoxic to mesothelial cells','Beta galacosidase colorimetric proliferation assay','1 MOI','98% cancer cell killing','No','No','NA','No response','NA','NA','NA','NA','10770637'),
  ('OV_854','Herpes simplex virus','HSV-G207','DNA','Herpesviridae','Deletion mutant in ICP34.5 and ICPC6 gene','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','Female CB17 SCID mice model xenograft for SKOV3 cell','5.0E+6 pfu','NA','Reduction in tumor growth to 50mg compared to control of 300mg within week','NA','NA','NA','NA','10770637'),
  ('OV_855','Adenovirus','CV890','DNA','Adenoviridae','E1A and E1B gene under control of Adenovirus promoter','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALBc nude mice with Hep3B cell xenograft','1.0E+11 pfu','NA','Complete reduction in tumor nodes','intraperitonial','NA','NA','NA','11522637'),
  ('OV_856','Adenovirus','CV890','DNA','Adenoviridae','E1A and E1B gene under control of Adenovirus promoter','No','Virus strain in combination with Doxorubicin (10ng/ml)','No','ATCC','Human hepatoma cell line','Hep3B','NA','NA','MTT assay','0.01pfu/cell','90% cancer cell killing after day 9, showing synergism with drug','No','No','NA','No response','NA','NA','NA','NA','11522637'),
  ('OV_857','Adenovirus','CV890','DNA','Adenoviridae','E1A and E1B gene under control of Adenovirus promoter','Yes','No','No','ATCC','Human hepatoma cell line','Hep3B','NA','NA','MTT assay','0.01pfu/cell','35% cancer cell killing after day 9','No','No','NA','No response','NA','NA','NA','NA','11522637'),
  ('OV_858','Measles virus','MV-Edm','RNA','Paramyxoviridae','Recombinant expressing a peptide','Yes','No','virus expressing a marker peptide (MV-hCEA)','Natural','NA','NA','NA','NA','NA','NA','NA','Female athymic mouse xenograft model for SKOV3 cell line','1.0E+7 pfu/ml','NA','Median survival time increased by >105 days','subcutaneous','NA','NA','NA','12183422'),
  ('OV_859','Measles virus','MV-Edm','RNA','Paramyxoviridae','Recombinant expressing a peptide','Yes','No','virus expressing a marker peptide (MV-hCEA)','Natural','NA','NA','NA','NA','NA','NA','NA','Female athymic mouse xenograft model for SKOV3 cell line','10⁷pfu/ml','NA','Median survival time increased by >80 days','intraperitonial','NA','NA','NA','12183422'),
  ('OV_860','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','1 MOI','94% cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_861','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','1 MOI','75 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_862','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','1 MOI','80 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_863','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','1 MOI','99% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_864','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','1 MOI','92% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_865','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','1 MOI','96% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_866','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','0.1 MOI','60% cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_867','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','0.1 MOI','40 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_868','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','0.1 MOI','60 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_869','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','0.1 MOI','95% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_870','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','0.1 MOI','80% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_871','Herpes simplex virus','BL1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','0.1 MOI','80% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_872','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','1 MOI','94% cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_873','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','1 MOI','85 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_874','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','1 MOI','85 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_875','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','1 MOI','98% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_876','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','1 MOI','96% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_877','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','1 MOI','97% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_878','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','0.1 MOI','60% cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_879','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','0.1 MOI','60 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_880','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','0.1 MOI','60 % cancerous cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_881','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Cellosaurus cell line','SK-MEL-28','NA','NA','MTT assay','0.1 MOI','95% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_882','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Triple-negative breast cancer cell line','MDA-MB-231','NA','NA','MTT assay','0.1 MOI','88% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_883','Herpes simplex virus','JS1','DNA','Herpesviridae','None','Yes','No','No','ATCC','Human colorectal adenocarcinoma cell line','HT-29','NA','NA','MTT assay','0.1 MOI','88% cancerous cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12595888'),
  ('OV_884','Herpes simplex virus','JS1','DNA','Herpesviridae','JS1 strain mutant in ICP34.5 and ICP47','Yes','No','No','ATCC','NA','NA','NA','NA','MTT assay','NA','NA','BALB/c nude mice xenograft for HT-29 cell','1.0E+8 pfu\n','NA','Compelte reduction of tumor after 28 days','intraperitonial','NA','Increase production of IFN-gamma','NA','12595888'),
  ('OV_885','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Hepatocellular carcinoma cell line','Hep3B','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.1 pfu/ml','75% cncer cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_886','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Glioblastoma cell line','U-87 MG','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.1 pfu/ml','85% cncer cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_887','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Human prostate cancer cell line','Du145','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.1 pfu/ml','85% cncer cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_888','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Hepatocellular carcinoma cell line','Hep3B','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.1 pfu/ml','95% cncer cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_889','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Glioblastoma cell line','U-87 MG','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.1 pfu/ml','90% cncer cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_890','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Human prostate cancer cell line','Du145','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.1 pfu/ml','95% cncer cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_891','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Hepatocellular carcinoma cell line','Hep3B','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.01 pfu/ml','70% cncer cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_892','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Glioblastoma cell line','U-87 MG','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.01 pfu/ml','75% cncer cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_893','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Human prostate cancer cell line','Du145','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.01 pfu/ml','80% cncer cell killing after 24 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_894','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Hepatocellular carcinoma cell line','Hep3B','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.01 pfu/ml','99% cncer cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_895','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Glioblastoma cell line','U-87 MG','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.01 pfu/ml','80% cncer cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_896','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','Human prostate cancer cell line','Du145','3.0E+4 cells per well','NA','Trypan blue staining and hematocytometer','0.01 pfu/ml','80% cncer cell killing after 48 hours','No','No','NA','No response','NA','NA','NA','NA','12788648'),
  ('OV_897','Herpes simplex virus','Mutant','DNA','Herpesviridae','Deletion mutant for Gamma 34.5','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','Hsd athymic nude mice xenograft for Hep 3B cancer cell line','1.0E+7 pfu\n','NA','Complete reduction in tumor nodes after 4 weeks','intraperitonial','NA','NA','NA','12788648'),
  ('OV_898','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','2% cancer cell killing after 24 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_899','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','20% cancer cell killing after 24 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_900','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','50% cancer cell killing after 24 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_901','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','20% cancer cell killing after 48 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_902','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','40% cancer cell killing after 48 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_903','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','80% cancer cell killing after 48 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_904','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','60% cancer cell killing after 72 hours','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_905','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','80% cancer cell killing after 72 hours','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_906','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.01 pfu/cell','90% cancer cell killing after 72 hours','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_907','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','20% cancer cell killing after 24 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_908','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','30% cancer cell killing after 24 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_909','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','50% cancer cell killing after 24 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_910','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','50% cancer cell killing after 48 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_911','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','60% cancer cell killing after 48 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_912','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','100% cancer cell killing after 48 hour','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_913','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','60% cancer cell killing after 72 hours','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_914','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','80% cancer cell killing after 72 hours','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_915','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','Prostate cancer cell line','PC-3M-Pro4','5.0E+4 cells per well','NA','Trypan blue staining','0.1 pfu/cell','100% cancer cell killing after 72 hours','No','No','NA','No response','NA','NA','NA','NA','15129429'),
  ('OV_916','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line','2.0E+7 pfu\n','NA','30% reduction in tumor volume','Tail vein injection of virus','NA','NA','NA','15129429'),
  ('OV_917','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line','2.0E+7 pfu\n','NA','50% reduction in tumor volume','Tail vein injection of virus','NA','NA','NA','15129429'),
  ('OV_918','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line','2.0E+7 pfu\n','NA','60% reduction in tumor volume','Tail vein injection of virus','NA','NA','NA','15129429'),
  ('OV_919','Herpes simplex virus','Baco-1','DNA','Herpesviridae','Non- fusogenic ligated with EGFP protein','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model','2.0E+7 pfu\n','NA','Lung metastasis were not detected after 40 days when stained with bouins fixative','Tail vein injection of virus','NA','NA','NA','15129429'),
  ('OV_920','Herpes simplex virus','Synco-2','DNA','Herpesviridae','Fusogenic membrane ligated with GALV.fus protein','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model','2.0E+7 pfu\n','NA','Lung metastasis were not detected after 40 days when stained with bouins fixative','Tail vein injection of virus','NA','NA','NA','15129429'),
  ('OV_921','Herpes simplex virus','Synco-2D','DNA','Herpesviridae','Double fusogenic expressing EGFP and GALV.fus protein','Yes','No','No','ATCC','NA','NA','NA','NA','NA','NA','NA','BALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model','2.0E+7 pfu\n','NA','Lung metastasis were not detected after 40 days when stained with bouins fixative','Tail vein injection of virus','NA','NA','NA','15129429'),
  ('OV_922','Adenovirus','CNHK-300','DNA','Adenoviridae','Addition of 3 hTERT promoter in E boxes of genome','Yes','No','No','Synthesized','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice','1.0E+9 pfu','NA','Tumor volume decreases to 600 mm3 after 20 days as compared to control','Tail vein injection of virus','NA','NA','NA','15243805'),
  ('OV_923','Adenovirus','ONYX-015','DNA','Adenoviridae','None','Yes','No','No','Onyx pharmaceutical','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice','1.0E+9 pfu','NA','Tumor volume decreases to 200 mm3 after 20 days as compared to control','Tail vein injection of virus','NA','NA','NA','15243805'),
  ('OV_924','Adenovirus','CNHK-300','DNA','Adenoviridae','Addition of 3 hTERT promoter in E boxes of genome','Yes','No','No','Synthesized','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice','1.0E+9 pfu','NA','Tumor volume decreases to 200 mm3 after 20 days as compared to control','Tail vein injection of virus','NA','NA','NA','15243805'),
  ('OV_925','Adenovirus','CNHK-300','DNA','Adenoviridae','Addition of 3 hTERT promoter in E boxes of genome','Yes','No','No','Synthesized','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice','5.0E+8 pfu\n','NA','Tumor volume decreases to 500 mm3 after 20 days as compared to control','Tail vein injection of virus','NA','NA','NA','15243805'),
  ('OV_926','Adenovirus','CNHK-300','DNA','Adenoviridae','Addition of 3 hTERT promoter in E boxes of genome','Yes','No','No','Synthesized','NA','NA','NA','NA','NA','NA','NA','BALB/c nude mice','1.0E+9 pfu','NA','Tumor volume decreases to 400 mm3 after 20 days as compared to control','Tail vein injection of virus','NA','NA','NA','15243805'),
  ('OV_927','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10 virus particle/cell','70% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_928','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_929','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_930','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','All cancer cell survive after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_931','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10 virus particle/cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_932','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','60% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_933','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','60% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_934','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','All cancer cell survive after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_935','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','10 virus particle/cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_936','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_937','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_938','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','90% cancer cell survive after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_939','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','10 virus particle/cell','90% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_940','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_941','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','70% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_942','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','70% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_943','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','10 virus particle/cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_944','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','70% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_945','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','70% cancer cell survival after 6 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_946','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_947','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','10 virus particle/cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_948','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_949','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','85% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_950','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','90% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_951','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','10 virus particle/cell','70% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_952','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','90% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_953','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_954','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_955','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','10 virus particle/cell','70% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_956','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','75% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_957','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','75% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_958','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','80% cancer cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_959','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10 virus particle/cell','90% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_960','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','90% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_961','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','60% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_962','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','20% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_963','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10 virus particle/cell','100% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_964','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','100% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_965','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','100% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_966','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_967','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','10 virus particle/cell','90% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_968','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','90% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_969','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','90% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_970','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-79','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_971','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','10 virus particle/cell','70% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_972','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','70% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_973','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','70% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_974','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','CHLA-20','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','70% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_975','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','10 virus particle/cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_976','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_977','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','50% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_978','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SKNBE','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','20% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_979','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','10 virus particle/cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_980','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_981','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','85% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_982','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','SMS-SAN','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','90% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_983','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','10 virus particle/cell','100% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_984','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','100% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_985','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','100% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_986','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','IMR-32','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','70% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_987','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','10 virus particle/cell','70% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_988','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','100 virus particle/ cell','75% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_989','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','1000 virus particle/ cell','75% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_990','Adenovirus','wild type','DNA','Adenoviridae','None','Yes','No','No','Alabama-Birmingham','Neuroblastoma cell line','Lan-5','4.0E+3 cells per well','NA','NA','10000 virus particle/ cell','80% cancer cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_991','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10 pfu/cell','90% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_992','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','100 pfu/cell','90% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_993','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','1000 pfu/cell','80% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_994','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10000 pfu/cell','60% cell kills after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_995','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10 pfu/cell','90% cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_996','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','100 pfu/cell','50% cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_997','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','1000 pfu/cell','20% cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_998','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10000 pfu/cell','100% cell kills after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_999','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10 pfu/cell','60% cell survival after 6 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1000','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','100 pfu/cell','100% cell kills after 6 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1001','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','1000 pfu/cell','100% cell kills after 6 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1002','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10000 pfu/cell','100% cell kills after 6 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1003','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10 pfu/cell','10% cell kills after 8 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1004','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','100 pfu/cell','100% cell kills after 8 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1005','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','1000 pfu/cell','100% cell kills after 8 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1006','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SK-N-SH','4.0E+3 cells per well','NA','NA','10000 pfu/cell','100% cell kills after 8 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1007','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10 pfu/cell','100% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1008','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','100 pfu/cell','100% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1009','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','1000 pfu/cell','100% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1010','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10000 pfu/cell','90% cell survival after 2 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
  ('OV_1011','Herpes simplex virus','HSV-1','DNA','Herpesviridae','Mutant NV1066','Yes','No','No','MediGene Inc. San Diego, CA','Neuroblastoma cell line','SHSY5Y','4.0E+3 cells per well','NA','NA','10 pfu/cell','100% cell survival after 4 days','No','No','NA','No response','NA','Apoptosis induction and cspase 3 activation','NA','NA','15570577'),
